Kendall Law Group Investigates Ev3, Inc. Merger For Shareholders

Kendall Law Group, a national securities firm, is investigating ev3, Inc. (NASDAQ: EVVV) for shareholders in connection with the proposed sale of ev3 to Covidien, plc. (NYSE: COV). The firm’s investigation seeks to determine whether ev3 and its Board breached their fiduciary duties by entering into the agreement without properly shopping for a deal that would provide better value for shareholders. If you are an ev3 shareholder and would like additional information about your rights, contact the Kendall Law Group at 877-744-3728 or by email at [e-mail].

The companies announced on June 1, 2010 that they had entered into an agreement for ev3 to be acquired by a subsidiary of Covidien in an all-cash tender offer valued at approximately $2.6 billion. ev3 is a “leading global medical device company focused on breakthrough endovascular treatments” with “over 100 products, with 15 new products launched in the last 12 months.” According to the agreement, Covidien would acquire all outstanding ev3 shares at $22.50 per share. By midday Tuesday, ev3 shares were trading for as high as $22.27 a share and had recently been upgraded to “market outperform” by BMO Capital Markets. The firm’s investigation concerns the process the Board of ev3 undertook in entering into the merger agreement and to determine if the agreement properly values the stock for shareholders.

Kendall Law Group was founded by a former federal judge, includes a former United States Attorney, prosecutors and securities lawyers who are experienced in complex securities litigation. The firm has been counsel in dozens of merger and acquisition cases nationwide, including some of the largest transactions in the United States.

>To order reprints of this article, click here: Reprints